nodes	percent_of_prediction	percent_of_DWPC	metapath
Maraviroc—Angina unstable—Riluzole—amyotrophic lateral sclerosis	0.0491	0.0524	CcSEcCtD
Maraviroc—Facial paralysis—Riluzole—amyotrophic lateral sclerosis	0.039	0.0416	CcSEcCtD
Maraviroc—Tetany—Riluzole—amyotrophic lateral sclerosis	0.038	0.0406	CcSEcCtD
Maraviroc—Osteonecrosis—Riluzole—amyotrophic lateral sclerosis	0.0333	0.0355	CcSEcCtD
Maraviroc—Dementia—Riluzole—amyotrophic lateral sclerosis	0.0302	0.0322	CcSEcCtD
Maraviroc—VIIth nerve paralysis—Riluzole—amyotrophic lateral sclerosis	0.0302	0.0322	CcSEcCtD
Maraviroc—Polyp—Riluzole—amyotrophic lateral sclerosis	0.0204	0.0217	CcSEcCtD
Maraviroc—Respiratory distress—Riluzole—amyotrophic lateral sclerosis	0.0195	0.0208	CcSEcCtD
Maraviroc—Cyst—Riluzole—amyotrophic lateral sclerosis	0.0186	0.0198	CcSEcCtD
Maraviroc—Blood creatine phosphokinase increased—Riluzole—amyotrophic lateral sclerosis	0.018	0.0192	CcSEcCtD
Maraviroc—Laryngitis—Riluzole—amyotrophic lateral sclerosis	0.0172	0.0184	CcSEcCtD
Maraviroc—Haemoptysis—Riluzole—amyotrophic lateral sclerosis	0.0168	0.0179	CcSEcCtD
Maraviroc—Neuritis—Riluzole—amyotrophic lateral sclerosis	0.0166	0.0177	CcSEcCtD
Maraviroc—Glaucoma—Riluzole—amyotrophic lateral sclerosis	0.0165	0.0176	CcSEcCtD
Maraviroc—Myocardial ischaemia—Riluzole—amyotrophic lateral sclerosis	0.0154	0.0165	CcSEcCtD
Maraviroc—Gamma-glutamyltransferase increased—Riluzole—amyotrophic lateral sclerosis	0.0151	0.0161	CcSEcCtD
Maraviroc—Ulcer—Riluzole—amyotrophic lateral sclerosis	0.0131	0.014	CcSEcCtD
Maraviroc—Cataract—Riluzole—amyotrophic lateral sclerosis	0.013	0.0139	CcSEcCtD
Maraviroc—Respiratory failure—Riluzole—amyotrophic lateral sclerosis	0.0126	0.0135	CcSEcCtD
Maraviroc—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.0112	0.012	CcSEcCtD
Maraviroc—Lymphadenopathy—Riluzole—amyotrophic lateral sclerosis	0.0106	0.0113	CcSEcCtD
Maraviroc—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.0103	0.011	CcSEcCtD
Maraviroc—Blood alkaline phosphatase increased—Riluzole—amyotrophic lateral sclerosis	0.0103	0.011	CcSEcCtD
Maraviroc—Vascular purpura—Riluzole—amyotrophic lateral sclerosis	0.0101	0.0107	CcSEcCtD
Maraviroc—Deafness—Riluzole—amyotrophic lateral sclerosis	0.0101	0.0107	CcSEcCtD
Maraviroc—Eczema—Riluzole—amyotrophic lateral sclerosis	0.01	0.0107	CcSEcCtD
Maraviroc—Amnesia—Riluzole—amyotrophic lateral sclerosis	0.00958	0.0102	CcSEcCtD
Maraviroc—Dermatitis exfoliative—Riluzole—amyotrophic lateral sclerosis	0.00954	0.0102	CcSEcCtD
Maraviroc—Purpura—Riluzole—amyotrophic lateral sclerosis	0.00934	0.00996	CcSEcCtD
Maraviroc—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.00822	0.00877	CcSEcCtD
Maraviroc—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.00813	0.00868	CcSEcCtD
Maraviroc—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00811	0.00865	CcSEcCtD
Maraviroc—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00794	0.00847	CcSEcCtD
Maraviroc—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.00783	0.00836	CcSEcCtD
Maraviroc—Influenza—Riluzole—amyotrophic lateral sclerosis	0.00778	0.0083	CcSEcCtD
Maraviroc—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.00763	0.00814	CcSEcCtD
Maraviroc—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.00758	0.00809	CcSEcCtD
Maraviroc—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.00748	0.00798	CcSEcCtD
Maraviroc—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.00739	0.00788	CcSEcCtD
Maraviroc—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.00727	0.00776	CcSEcCtD
Maraviroc—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.00698	0.00744	CcSEcCtD
Maraviroc—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00694	0.0074	CcSEcCtD
Maraviroc—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00694	0.0074	CcSEcCtD
Maraviroc—Depression—Riluzole—amyotrophic lateral sclerosis	0.00692	0.00738	CcSEcCtD
Maraviroc—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.00684	0.0073	CcSEcCtD
Maraviroc—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.0068	0.00725	CcSEcCtD
Maraviroc—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.0068	0.00725	CcSEcCtD
Maraviroc—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.00676	0.00721	CcSEcCtD
Maraviroc—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.00676	0.00721	CcSEcCtD
Maraviroc—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00656	0.007	CcSEcCtD
Maraviroc—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.00651	0.00694	CcSEcCtD
Maraviroc—Agranulocytosis—Riluzole—amyotrophic lateral sclerosis	0.00647	0.00691	CcSEcCtD
Maraviroc—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.00624	0.00666	CcSEcCtD
Maraviroc—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.0062	0.00661	CcSEcCtD
Maraviroc—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.00618	0.00659	CcSEcCtD
Maraviroc—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00615	0.00656	CcSEcCtD
Maraviroc—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.00612	0.00653	CcSEcCtD
Maraviroc—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.0061	0.00651	CcSEcCtD
Maraviroc—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.00589	0.00628	CcSEcCtD
Maraviroc—CCR5—spinal cord—amyotrophic lateral sclerosis	0.00584	0.289	CbGeAlD
Maraviroc—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.00582	0.00621	CcSEcCtD
Maraviroc—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00578	0.00617	CcSEcCtD
Maraviroc—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00565	0.00603	CcSEcCtD
Maraviroc—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00561	0.00599	CcSEcCtD
Maraviroc—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.0055	0.00587	CcSEcCtD
Maraviroc—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00546	0.00582	CcSEcCtD
Maraviroc—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00542	0.00578	CcSEcCtD
Maraviroc—CCR5—HIV Life Cycle—VTA1—amyotrophic lateral sclerosis	0.00535	0.126	CbGpPWpGaD
Maraviroc—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00534	0.0057	CcSEcCtD
Maraviroc—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00508	0.00542	CcSEcCtD
Maraviroc—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00501	0.00535	CcSEcCtD
Maraviroc—CCR5—nervous system—amyotrophic lateral sclerosis	0.00492	0.243	CbGeAlD
Maraviroc—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00486	0.00519	CcSEcCtD
Maraviroc—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.00485	0.00518	CcSEcCtD
Maraviroc—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00476	0.00508	CcSEcCtD
Maraviroc—CCR5—central nervous system—amyotrophic lateral sclerosis	0.00474	0.234	CbGeAlD
Maraviroc—Cough—Riluzole—amyotrophic lateral sclerosis	0.00473	0.00505	CcSEcCtD
Maraviroc—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.0047	0.00501	CcSEcCtD
Maraviroc—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.00462	0.00492	CcSEcCtD
Maraviroc—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.0046	0.00491	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00458	0.00489	CcSEcCtD
Maraviroc—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.00456	0.00486	CcSEcCtD
Maraviroc—CCR5—Peptide GPCRs—C5AR1—amyotrophic lateral sclerosis	0.00453	0.107	CbGpPWpGaD
Maraviroc—Oedema—Riluzole—amyotrophic lateral sclerosis	0.00442	0.00472	CcSEcCtD
Maraviroc—Infection—Riluzole—amyotrophic lateral sclerosis	0.0044	0.00469	CcSEcCtD
Maraviroc—Shock—Riluzole—amyotrophic lateral sclerosis	0.00435	0.00464	CcSEcCtD
Maraviroc—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00434	0.00463	CcSEcCtD
Maraviroc—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.0043	0.00458	CcSEcCtD
Maraviroc—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00422	0.0045	CcSEcCtD
Maraviroc—CCR5—HIV Life Cycle—CHMP2B—amyotrophic lateral sclerosis	0.00406	0.0956	CbGpPWpGaD
Maraviroc—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00403	0.0043	CcSEcCtD
Maraviroc—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.004	0.00427	CcSEcCtD
Maraviroc—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.00397	0.00424	CcSEcCtD
Maraviroc—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.00385	0.0041	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00382	0.00407	CcSEcCtD
Maraviroc—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00381	0.00407	CcSEcCtD
Maraviroc—Pain—Riluzole—amyotrophic lateral sclerosis	0.00378	0.00404	CcSEcCtD
Maraviroc—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00378	0.00404	CcSEcCtD
Maraviroc—CCR5—brain—amyotrophic lateral sclerosis	0.00376	0.186	CbGeAlD
Maraviroc—CCR5—HIV Infection—VTA1—amyotrophic lateral sclerosis	0.0037	0.0871	CbGpPWpGaD
Maraviroc—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00362	0.00386	CcSEcCtD
Maraviroc—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.0035	0.00373	CcSEcCtD
Maraviroc—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.0035	0.00373	CcSEcCtD
Maraviroc—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00326	0.00348	CcSEcCtD
Maraviroc—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00317	0.00339	CcSEcCtD
Maraviroc—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00313	0.00334	CcSEcCtD
Maraviroc—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00303	0.00323	CcSEcCtD
Maraviroc—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00293	0.00312	CcSEcCtD
Maraviroc—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00281	0.003	CcSEcCtD
Maraviroc—CCR5—HIV Infection—CHMP2B—amyotrophic lateral sclerosis	0.0028	0.066	CbGpPWpGaD
Maraviroc—Rash—Riluzole—amyotrophic lateral sclerosis	0.00279	0.00298	CcSEcCtD
Maraviroc—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00279	0.00297	CcSEcCtD
Maraviroc—Headache—Riluzole—amyotrophic lateral sclerosis	0.00277	0.00296	CcSEcCtD
Maraviroc—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00263	0.0028	CcSEcCtD
Maraviroc—CCR5—Peptide ligand-binding receptors—C5AR1—amyotrophic lateral sclerosis	0.00213	0.0502	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—C5AR1—amyotrophic lateral sclerosis	0.0018	0.0423	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.00143	0.0336	CbGpPWpGaD
Maraviroc—CCR5—Disease—TPK1—amyotrophic lateral sclerosis	0.00113	0.0267	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.00109	0.0256	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—C3—amyotrophic lateral sclerosis	0.000929	0.0219	CbGpPWpGaD
Maraviroc—CCR5—Disease—VTA1—amyotrophic lateral sclerosis	0.000906	0.0214	CbGpPWpGaD
Maraviroc—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.000795	0.0187	CbGpPWpGaD
Maraviroc—CCR5—G alpha (i) signalling events—C3—amyotrophic lateral sclerosis	0.000784	0.0185	CbGpPWpGaD
Maraviroc—CCR5—Disease—CHMP2B—amyotrophic lateral sclerosis	0.000687	0.0162	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000623	0.0147	CbGpPWpGaD
Maraviroc—CCR5—Disease—PLB1—amyotrophic lateral sclerosis	0.000621	0.0146	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000614	0.0145	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000558	0.0131	CbGpPWpGaD
Maraviroc—CCR5—Disease—VCP—amyotrophic lateral sclerosis	0.000554	0.013	CbGpPWpGaD
Maraviroc—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.000496	0.0245	CbGeAlD
Maraviroc—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000478	0.0236	CbGeAlD
Maraviroc—CCR5—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000475	0.0112	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000435	0.0102	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000409	0.00963	CbGpPWpGaD
Maraviroc—CCR5—Disease—CST3—amyotrophic lateral sclerosis	0.000397	0.00936	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000388	0.00913	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000375	0.00885	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000333	0.00785	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.00033	0.00777	CbGpPWpGaD
Maraviroc—CCR5—Disease—CASP9—amyotrophic lateral sclerosis	0.000289	0.00681	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000276	0.00649	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.000268	0.00632	CbGpPWpGaD
Maraviroc—CCR5—Disease—ERBB4—amyotrophic lateral sclerosis	0.000247	0.00583	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.000244	0.00574	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000226	0.00534	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000212	0.005	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000206	0.00486	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.000202	0.00477	CbGpPWpGaD
Maraviroc—CCR5—Disease—APOE—amyotrophic lateral sclerosis	0.000191	0.00451	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	0.000173	0.00408	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	0.000163	0.00384	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—C3—amyotrophic lateral sclerosis	0.000144	0.00339	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—APOE—amyotrophic lateral sclerosis	0.000134	0.00316	CbGpPWpGaD
Maraviroc—CCR5—Disease—PTGS2—amyotrophic lateral sclerosis	0.000131	0.00309	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	0.000111	0.00261	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	9.23e-05	0.00218	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	9.11e-05	0.00215	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	8.52e-05	0.00201	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	8.05e-05	0.0019	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	7.23e-05	0.0017	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	7.08e-05	0.00167	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	7.08e-05	0.00167	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	6.47e-05	0.00152	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	6.02e-05	0.00142	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	5.66e-05	0.00133	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TP53—amyotrophic lateral sclerosis	5.46e-05	0.00129	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	5.12e-05	0.00121	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	3.88e-05	0.000913	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	3.58e-05	0.000843	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	2.94e-05	0.000692	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.58e-05	0.000372	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.45e-05	0.000342	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	1.19e-05	0.000281	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	8.18e-06	0.000193	CbGpPWpGaD
